Sanofi’s new dengue challenge: find a diagnostic that will make its vaccine safe to use

Newly published data reveal in greater depth the problem Sanofi Pasteur’s Dengvaxia vaccine poses to children who have never experienced a dengue infection.

The findings, first revealed by the company last November, were the basis of an April decision by a World Health Association expert panel to recommend the vaccine only be given to children who have tested positive for a prior dengue infection. There is no such test at the moment.